Papers/PMID:35631193
Astaxanthin Influence on Health Outcomes of Adults at Risk of Metabolic Syndrome: A Systematic Review and Meta-Analysis.
Nutrients2022The record
2 findings drawn from this paper, on 1 compound across 2 endpoints.
What it reported
How to read these marksWhat moved
2 findings
astaxanthin — decreases systolic blood pressure (setting unspecified)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“Subgroup analysis exhibited that the SBP was reduced significantly when AST was administered for more than 8 weeks (MD = −4.69; 95% CI = −9.23, −0.16; I2 = 0%; p = 0.04) (Supplementary File S6 Figure S4a).”
Quoted verbatim from Astaxanthin Influence on Health Outcomes of Adults at Risk of Metabolic Syndrome: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Population
- adults with metabolic syndrome risk factors; subgroup: AST administered for more than 8 weeks (pooled meta-analysis subgroup)
Effect -4.69 mean difference, 95% CI -9.23 to -0.16
Astaxanthin Influence on Health Outcomes of Adults at Risk of Metabolic Syndrome: A Systematic Review and Meta-Analysis.2022PMID:35631193
astaxanthin — increases LDL cholesterol
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“However, AST significantly increased the level of LDL-C (MD = 0.64; 95% CI = 0.64, 0.89; I2 = 0%; p < 0.00001;, regardless the duration of consumption and dosage of administration (Supplementary File S6 Figure S8a,b).”
Quoted verbatim from Astaxanthin Influence on Health Outcomes of Adults at Risk of Metabolic Syndrome: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Population
- adults with metabolic syndrome risk factors (CTS, T2DM, obesity, hypertension, renal transplant recipients); meta-analysis pooling 7 RCTs
Effect 0.64 mean difference, 95% CI 0.64 to 0.89
Astaxanthin Influence on Health Outcomes of Adults at Risk of Metabolic Syndrome: A Systematic Review and Meta-Analysis.2022PMID:35631193